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Abstract
We report on a method to improve in vitro diagnostic assays that detect immune response, with specific application to HIV-
1. The inherent polyclonal diversity of the humoral immune response was addressed by using sequential in situ click
chemistry to develop a cocktail of peptide-based capture agents, the components of which were raised against different,
representative anti-HIV antibodies that bind to a conserved epitope of the HIV-1 envelope protein gp41. The cocktail was
used to detect anti-HIV-1 antibodies from a panel of sera collected from HIV-positive patients, with improved signal-to-noise
ratio relative to the gold standard commercial recombinant protein antigen. The capture agents were stable when stored as
a powder for two months at temperatures close to 60oC.
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Introduction
Detecting the immune response to an infectious agent can
provide a useful in vitro diagnostic surrogate relative to direct
pathogen detection [1]. Such assays are commonly used for
detecting HIV infection because of its characteristic immunopa-
thology [2]. Direct detection of HIV viral RNA and p24 antigen is
only effective at an early stage of infection, approximately 2–6
weeks of initial exposure [3,4]. Antibodies against HIV envelope
proteins emerge in patients’ blood around 3–4 weeks of infection
[2,5] as the viral RNA and p24 levels decline as a result of
immunocomplex formation [6]. The high serum level of anti-HIV
IgG is maintained throughout the course of clinical latency (2–20+
years), during which time viral antigens are under detection limits
until the onset of acquired immunodeficiency syndrome (AIDS)
[2,5]. Viral load and CD4+ cell counts are mainly used for
prognostic purposes to monitor the efficacy of treatments; however
viral load is sometimes used for the diagnosis of infant HIV
infections where antibody-based assays are not applicable [3,7].
Assays for anti-HIV antibodies are the most widely used diagnostic
test both in cases where infection is presumed to have occurred
more than 6 weeks prior to testing, and for epidemiological
reasons, to estimate the incidence of HIV in a population [8],
since, with the exception of infant HIV, virtually 100% of the
infected individuals express these antibodies [3]. Typically in these
assays, immunogenic and conserved antigens from the HIV are
expressed as regions of a single chimeric protein. That chimeric
protein is then used to capture specific antibodies from the body
fluid (e.g. blood, saliva or urine) of potentially infected patients; a
positive assay result implies infection. However, the polyclonal
diversity of antibodies across a patient population can translate
into large variations in assay performance from patient to patient.
In addition, the chimeric recombinant proteins are biological
reagents, and so may have limitations related to shelf life and
batch-to-batch variability. These limitations can adversely influ-
ence the performance of a diagnostic test [3,5,9], especially one
that is deployed in harsh physical environments.
Here we report on the use of iterative in situ click chemistry
[10,11] to prepare a cocktail of chemically synthesized capture
agents (called protein-catalyzed capture agents, or PCC Agents)
that is designed to sample the polyclonal diversity of an antibody-
based immune response. We demonstrate the concept by
developing a PCC Agent-based assay designed to detect human
antibodies that bind to a conserved region of the HIV-1 envelope
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glycoprotein gp41. The performance of that assay is compared
against the gold standard chimeric protein antigen using sera
collected from a cohort of HIV-1-positive human subjects, plus
controls. We also report on the thermal stability of the capture
agent cocktail, with an eye towards point-of-care HIV diagnostics
assays that are needed in environments where refrigeration chains
may not exist.
Materials and Methods
For detailed protocols see Materials and Methods S1.
Ethics Statement
All study documents and procedures regarding the patient
serum assays were approved by the UCLA and Caltech
Institutional Review Boards. All subjects provided written
informed consent prior to initiation of study procedures.
Results and Discussion
The development of a PCC Agent against a protein target
utilizes the target itself to promote the 1,3-dipolar cycloaddition
between an acetylene and an azide group to form a triazole linkage
(the in situ ‘click’ reaction) [12]. The protein effectively plays the
role of an extremely selective, but much less efficient, variant of the
Cu(I) catalyst that is commonly used for such couplings [13,14].
For the present work, the two reacting species are peptides – one
peptide (the anchor) is a chemically modified variant of a
conserved, immunogenic epitope on the HIV-1 gp41 protein,
and the second peptide is selected via an in situ click screen from a
large (106 element) one-bead-one-compound (OBOC) [15] pep-
tide library. The protein targets are human monoclonal antibodies
raised against variants of the gp41 epitope represented by the
anchor peptide.
The PCC Agents developed here were designed to capture
antibodies that are selective for residues 600–612 (IWCGSGK-
LICTTA) of gp41. Previous studies have shown that a large
fraction of HIV-1-positive patients develop antibodies against this
epitope [16,17]. Our strategy for sampling the polyclonal diversity
of such antibodies was to develop PCC Agents that exhibited both
differential, as well as similar avidities for human monoclonal
antibodies (mAbs) raised against different parts of this epitope. A
key decision in this regard involves the selection of the anchor
peptides from which the PCC Agents are developed. For this task,
we modified the polypeptide fragment corresponding to residues
600–612 of gp41 with artificial amino acids at multiple locations,
and tested the ability of these modified peptides to detect two
different monoclonal anti-gp41 antibodies 3D6 and 4B3 (Poly-
mun, Klosterneuburg, Austria). The 3D6 mAb was raised against
the epitope SGKLIC, whereas the 4B3 mAb was raised against
SGKLICTTA. One anchor peptide, A21, was synthesized by
adding a propargyl glycine (Pra) residue at the C-terminus of the
residues 600–612 of gp41. This anchor peptide was also N-
terminally tagged with a polyethylene glycol (PEG) oligomer
bridge and a biotin label. For a second anchor peptide (A22), Leu-
607 was substituted with Pra. A22 also included an N-terminal
PEG-biotin label. A21 equally detected 3D6 and 4B3 with an
estimated dissociation constant (Kd) of 1–50 nM, while A22
differentially detected 3D6 (Kd.10 mM) and 4B3 (Kd=1–50 nM)
(Figure S1 in Supporting Information). A21 and A22 were then
separately developed into PCC agents against 3D6 and 4B3,
respectively.
The in situ click screens are illustrated in Figure 1. The target
IgG is incubated with an excess of the selected anchor peptide and
a large OBOC library at 4oC overnight (see Materials and
Methods S1). The OBOC library is synthesized on TentaGel
resin (Rapp Polymere, Tuebingen, Germany), and is a compre-
hensive library of 5-mers with a 6th amino acid at the N-terminus
presenting an azide functionality. To help ensure chemical and
biochemical stability, the OBOC library is comprised of non-
natural (D) stereoisomers of the 20 natural amino acids, excluding
cysteine and methionine. The in situ screen is designed to identify a
secondary (2o) peptide that, when coupled to the anchor, forms a
biligand with increased selectivity and/or affinity for the target
IgG. The screen proceeds stepwise. In the first step (not shown in
Figure 1) the OBOC library is cleared of beads that exhibit non-
specific binding to alkaline phosphatase-conjugated streptavidin
(SA-AP), which is used as a detection reagent in a later step. Step 2
is a target screen, and so is designed to detect the presence of the
bound IgG target to specific beads, and defines possible hits. The
step 3 screen is designed to remove those beads from the pool of
potential hits that also exhibit binding to off-target serum proteins.
Step 4 is called a product screen, and is unique to sequential in situ
click screens [11]. This screen is designed to detect for the
presence of in situ clicked reaction products, which are those hit
beads containing the triazole-linked anchor peptide. Typically,
Step 2 yields a few hundred hits (,0.05% of the OBOC library).
Step 3 reduces that pool by a factor of 2 or 3 to about 100 hits,
and Step 4 further reduces the number of hits to around 10. This is
a manageable number, meaning that each hit can be separately
synthesized as a biligand using Cu(I) catalyzed click chemistry to
couple the anchor and 2u peptides. The performance of these
biligands is then characterized using immunoprecipitation (pull-
down) assays detected by Western blotting from spiked serum
samples for specificity (data not shown), and sandwich ELISAs and
surface plasmon resonance (SPR) assays for affinity estimations
(Figure S2, Figure S3). A complete list of the hits for the A21/
3D6 and A22/4B3 screens is given in Table S1. This approach
yielded two equivalently performing biligands against 3D6, and
one biligand against 4B3 (Figures S2, Figure S3). These three
PCC agents (Figure 2) were combined, in equal parts, to form a
capture agent cocktail. The cocktail slightly outperformed both the
standard commercial chimeric antigen and A21, when tested
against healthy human serum spiked with both 3D6 and 4B3
(Figure S4). A21 is the equivalent of the original antigenic epitope
of gp41.
The PCC Agent cocktail and the standard antigen were co-
evaluated against a panel of clinical samples using sandwich
ELISAs. Serum samples were collected from nine HIV-1-positive
patients in Southern California. The standard antigen is a
recombinant chimeric protein containing a fragment of HIV-1
gp41 (residues 546–692), the ‘‘O’’ group HIV-1 gp41 immuno-
dominant region (residues 580–623), and a fragment of HIV-2
gp36 (residues 591–617). A good performance of this chimeric
antigen has been reported elsewhere [18]. For the comparison
assays, streptavidin-coated 96-well plates were saturated with the
PCC Agent cocktail or chemically biotinylated chimera in
triplicates. Serum samples were diluted to 1% v/v in Tris-buffered
saline (TBS) supplemented with 0.1% w/v bovine serum albumin
(BSA), and incubated in the wells for 1 hr at room temperature.
Unbound proteins were washed off and captured IgG was detected
with a peroxidase-conjugated mouse monoclonal anti-human IgG-
Fc antibody. The comparison assay results for the patient serum
samples along with a healthy control are shown in Figure 3A.
The signal-to-noise (S/N) ratio in these assays is defined as the
measured ELISA signal for a given patient sample, divided by that
for the healthy control. The PCC Agent cocktail performed at
least as well, and typically much better, than the standard chimeric
Capture Agents for Detecting Anti-Gp41 Antibodies
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Figure 1. Screening strategy for selecting capture agents against anti-HIV antibodies 3D6 and 4B3. The flow chart represents the use of
the A21 and A22 cyclic peptides as anchor ligands for separate in situ click screens against a large OBOC azide-presenting peptide library.
doi:10.1371/journal.pone.0076224.g001
Figure 2. Structures of peptide ligands in PCC Agent cocktail. Acetylene-presenting anchor peptides (black) were derived from the
immunogenic epitope of HIV-1 gp41 (residues 600–612). A22-nindG (i) and A21-hnpfk (ii) were evolved from the original epitope appended with Pra
at the C-terminus whereas A22-eihny (iii) utilizes the ‘‘substituted’’ anchor where residue Leu-607 is replaced with Pra. Secondary ligand branches
(colored) were identified from the in situ click screen of a 5-mer OBOC library presenting an azide functionality. Biligands (i) and (ii) were raised
against the target anti-HIV antibody 3D6, and the biligand (iii) was raised against the antibody 4B3.
doi:10.1371/journal.pone.0076224.g002
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protein antigen. The average S/N improvement by the cocktail
PCC agent over the chimeric antigen was a factor of 2.5.
We then tested the PCC Agents for thermal stability. The PCC
Agent cocktail component (iii) were synthesized at a large scale
for an academic setting (,7 mg, Figure 3B) and the lyophilized
samples were stored under N2 at 25uC, 37uC, or 57uC for 58 days.
The samples were then analyzed by HPLC to determine the
presence of any degradation product. The traces of the peptide at
each temperature are nearly identical, indicating little to no
degeneration at these temperatures (Figure 3B). The perfor-
mance of these stored PCC Agents was then also tested in an
ELISA, with no detectable loss of performance (Figure 3B).
Conclusion
We describe here a method for developing a PCC Agent
cocktail to capture the diversity of human antibodies generated in
response to an infectious agent. We demonstrated the successful
application of this method for HIV-1 diagnostics by producing a
cocktail of three PCC Agents that detected the presence of anti-
HIV antibodies in clinical samples with a significantly enhanced
signal-to-noise relative to the standard, recombinant protein-based
chimeric antigen. In a recent report, an antigenic peptide cocktail
comprised of synthetic peptides derived directly from gp120/V3-I
(HIV-1 Indian isolate), gp41 (HIV-1), and gp36 (HIV-2), as well as
the recombinant protein rp24 (HIV-1) was shown to also provide
superior performance relative to the chimeric antigen [19]. This
points to the possibility that expanding the current approach by
developing multiple cocktails of PCC Agents, each directed against
a distinct HIV epitope, would likely provide superior performance
to that reported here. The strategy presented provides a promising
approach for developing assays for detecting the immune response
to other infectious agents, especially where challenges associated
with the polyclonal nature of a humoral immune response can
compromise assay sensitivity.
Supporting Information
Materials and Methods S1 Detailed experimental protocols.
(DOCX)
Figure S1 Differential detection of 3D6 and 4B3 by
anchor ligands. Relative affinities of A21 and A22 for 3D6 and
4B3 were determined by sandwich ELISA. Biotinylated anchor
ligands A21 and A22 were immobilized on streptavidin-coated 96-
well plated at a concentration of 100 nM, and incubated with the
solutions of target anti-HIV antibodies 3D6 and 4B3 at 100 nM in
TBS. Captured antibody was detected by peroxidase-conjugated
anti-human IgG antibody.
(TIF)
Figure S2 Apparent affinity of A21 and biligands
directed against 3D6 as determined by SPR. A. Sensor-
gram and 1st order Hill fit to affinity data for A21. B. Sensorgram
and 1st order Hill fit to affinity data for A21-nidnG (i). C.
Sensorgram and 1st order Hill fit to affinity data for A21-hnpfk
(ii).
(TIF)
Figure S3 Apparent affinity of A22 and biligand directed
against 4B3 as determined by SPR. A. Sensorgram and 1st
order Hill fit to affinity data for A22. B. Sensorgram and 1st order
Hill fit to affinity data for A22-eihny (iii).
Figure 3. Performance of the PCC Agent cocktail, and thermal stability and scale up of a cocktail component. A. Comparative
performance of the PCC Agent cocktail versus the commercial chimeric protein, using sandwich ELISAs to detect anti-HIV-1 IgGs from a panel of sera
samples collected from nine HIV-positive patients. The absorbance at 450 nm (A450) for each sample is normalized against the A450 for the healthy
control, to yield a measurement of the signal-to-noise ratio of the assay. The PCC Agent cocktail, which is designed to capture a subset of anti-gp41
IgGs, exhibits superior performance for every sample, even though the chimeric protein is designed to capture antibodies against multiple HIV-1-
associated epitopes (those containing fragments of HIV-1 gp41, ‘‘O’’ group HIV-1 gp41 immunodominant region, and HIV-2 gp39). For the assays, the
PCC agent cocktail and the biotinylated chimeric antigen were immobilized on a streptavidin-coated 96-well plate and incubated with diluted patient
serum (1% v/v). Captured anti-HIV antibodies were detected using peroxidase-conjugated anti-human IgG antibody. B. Samples of (iii) were stored
as a powder (inset photo), under N2 at temperatures up to 57uC for ,2 months, and resolved by analytical HPLC to determine the presence of any
degradation product. The HPLC traces reveal that the fingerprint of the PCC Agent is unchanged. The inset shows that the assay performance of the
PCC Agent is also unaffected.
doi:10.1371/journal.pone.0076224.g003
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(TIF)
Figure S4 Performance of PCC agent cocktail to detect
3D6 and 4B3 from human serum. Comparative performance
of the PCC Agent cocktail versus the original gp41 epitope A21
and the commercial chimeric protein antigen was tested by a
sandwich ELISA. Target antibodies 3D6 and 4B3 (4 nM each)
were both spiked into diluted, HIV-free human serum (1% v/v in
TBS), and captured antibody was detected by peroxidase-
conjugated anti-human IgG antibody.
(TIF)
Table S1 Biligand screen results. List of pentapeptide
‘‘hits’’ from OBOC biligand screens performed with A21/3D6
and A22/4B3. The selected secondary ligands corresponding to
(i), (ii), and (iii) are in bold.
(TIF)
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